New T‑cell therapy targets three tumor proteins, shows early survival gains in aggressive pediatric brain cancers
· Medical Xpressby Beth Riggs, Children's National Hospital
edited by Stephanie Baum, reviewed by Robert Egan
Stephanie Baum
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Researchers report encouraging early results from a first-in-human clinical trial led by Children's National Hospital using a new T-cell immunotherapy for children and young adults with some of the deadliest brain tumors, including diffuse intrinsic pontine glioma (DIPG) and relapsed central nervous system (CNS) tumors. These findings, published in Nature Medicine, are particularly significant given the challenges of treating pediatric brain tumors, which remain the leading cause of cancer-related deaths in children. Immunotherapies have been shown to work in blood cancers but rarely succeed in solid tumors, especially brain tumors.
"This study represents an important step toward developing safer and more effective T-cell therapies for children with devastating brain cancers," said Catherine Bollard, MBChB, MD, senior vice president and chief research officer at Children's National, and co-senior author of the study. "Even in this early-stage trial focused on safety, we were encouraged to see lasting clinical benefit in several patients who otherwise had very few options."
Three targets, fewer severe side effects
The phase 1 study evaluated a novel multitargeted T-cell therapy designed to strike three proteins commonly found in pediatric brain tumors—WT1, PRAME and survivin. Investigators say the results provide early evidence that the patient's own immune cells, delivered through the bloodstream, can reach and fight tumors in the brain while producing fewer severe side effects than some existing engineered immune therapies. Many other brain tumor immunotherapies require direct injection into the brain or cerebrospinal fluid.
"We were excited to see that we could preserve safety and quality of life while generating antitumor responses by attacking three targets at once," said Eugene Hwang, MD, chief of oncology at Children's National and co-senior author of the study.
Key takeaways include:
- The multitarget design may help address tumor heterogeneity, one of the major barriers to successful treatment of aggressive childhood cancers.
- The trial successfully established a feasible manufacturing process, identified a maximum tolerated dose and defined an early safety profile—key milestones needed to advance the therapy into future phase 2 studies.
- Researchers analyzed patients with DIPG or relapsed brain cancers, showing both responses and prolonged disease control, with some patients remaining disease-free years after treatment.
"Pediatric tumors are one of the greatest challenges in cancer research, with children still facing extremely limited treatment options, and existing treatments often causing severe side effects," said David Scott, director of Cancer Grand Challenges, which supports the NexTGen team, a group of international collaborators co-led by Bollard that is taking on the "solid tumors in children" Cancer Grand Challenge.
Publication details
Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial, Nature Medicine (2026). DOI: 10.1038/s41591-026-04449-9
Journal information: Nature Medicine
Key medical concepts
Clinical categories
OncologyChildren's healthPediatricsNeurology Provided by Children's National Hospital Who's behind this story?
Stephanie Baum
Master's in TESOL from The New School. Passionate about language learning and editing science news on biology and space exploration. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: New T‑cell therapy targets three tumor proteins, shows early survival gains in aggressive pediatric brain cancers (2026, June 30) retrieved 1 July 2026 from https://medicalxpress.com/news/2026-06-tcell-therapy-tumor-proteins-early.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.